# NAD+

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Compound
Updated: 2026-10-14
Canonical: https://heretic.bio/articles/nad-and-sirtuin-activators.html

> NAD+ is a cofactor every cell needs for energy production, DNA repair and sirtuin signaling. Multiple randomized trials show the oral precursors NR and NMN reliably raise blood NAD+, and a 2026 crossover trial showed NR raises brain NAD+ in humans. The caveats are large: whole-blood NAD+ does not actually decline with age (2026 Nature Metabolism), 24 weeks of high-dose NMN produced no functional benefit, and no trial shows lifespan extension. IV NAD+ rests on anecdotes and small uncontrolled reports.

> NAD+ (nicotinamide adenine dinucleotide) is the master metabolic cofactor — required by every living cell for energy production, DNA repair, and epigenetic regulation. Precursors (NMN, NR) reliably raise blood NAD+ in humans, and NR has now been shown to raise _brain_ NAD+ (Berven 2026). **However, the foundational "NAD+ declines ~50% with age" claim took a major hit in 2026** : whole-blood NAD+ does not measurably decline with age (Trętowicz, _Nature Metabolism_ 2026). Tissue-level (muscle, brain) decline remains supported by animal data — the blood compartment is not the tissue compartment. See [NAD+ Precursor Market in Crisis - Nature Metabolism 2026](nad-and-sirtuin-activators.html) for the market impact.

## NAD+ Biology

### Functions of NAD+

  1. **Redox cofactor:** Shuttles electrons in mitochondria (NAD+/NADH ratio governs energy production)
  2. **Sirtuin substrate:** SIRT1-7 require NAD+ for deacetylase activity → gene regulation
  3. **PARP substrate:** DNA repair enzyme consumes NAD+
  4. **CD38 substrate:** Immune/aging-related enzyme that degrades NAD+
  5. **SARM1 substrate:** Nerve degeneration pathway



### Why NAD+ Declines — 2026 Correction

**The classic narrative (now partly disconfirmed):** age reduces synthesis (NAMPT decline), CD38 upregulation degrades NAD+, PARP activation consumes it.

**The 2026 correction (Trętowicz et al.,_Nature Metabolism_ , PMID [42135539](https://pubmed.ncbi.nlm.nih.gov/42135539/)):** in 7 independent cohorts (n > 300, ages 18–87) with validated mass-spectrometry assays, **whole-blood NAD+ does not vary with age** — nor with exercise or protein supplementation. Earlier "age-related decline" findings traced substantially to assay artifacts (freeze–thaw cycles, enzymatic vs. mass-spec methods). NR still raised blood NAD+ 4–6× in responders, confirming precursors work on the blood compartment.

**What survives:** \- **Tissue-level decline** (muscle, liver, brain) remains well-supported in animal models — blood is not brain. \- CD38/PARP consumption pathways remain mechanistically real; the question is compartment and assay, not mechanism. \- The "50% decline by 60" marketing number is not supported for whole blood and should not be used in client education without the compartment caveat.

Factor | Mechanism | 2026 status  
---|---|---  
**Age** | Reduced synthesis (NAMPT enzyme declines) | **Disconfirmed for whole blood** (Trętowicz 2026); animal tissue data intact  
**CD38 upregulation** | Inflammatory/immune cells express more CD38 with age → NAD+ degradation | Mechanism intact; human blood data now contested  
**PARP activation** | DNA damage increases → more PARP activity → NAD+ consumption | Mechanism intact  
**Circadian disruption** | NAMPT is circadian-regulated; poor sleep reduces NAD+ synthesis | Unchanged  
  
## NAD+ Precursors

### Nicotinamide Riboside (NR)

  * **Form:** Niagen® (patented, most studied)
  * **Pathway:** NR → NMN → NAD+
  * **Evidence:** Raises NAD+ levels in humans (PMID [29555780](https://pubmed.ncbi.nlm.nih.gov/29555780/))
  * **2026 upgrade — brain penetration:** The NAD-Brain PK study (Berven et al., _iScience_ 2026, PMID [41858901](https://pubmed.ncbi.nlm.nih.gov/41858901/); 1,200 mg/day, crossover, healthy adults + Parkinson's patients) showed 4 weeks of NR raised **brain NAD+ measured by ³¹P-MRS** — first direct human demonstration of cerebral NAD+ augmentation from an oral precursor. NR raised blood NAD+ ~2.3× more than NMN at gram-equivalent doses (161% vs 69%).
  * **Limitation:** Most is converted to nicotinamide (NAM) in the liver, which inhibits sirtuins at high levels



### Nicotinamide Mononucleotide (NMN)

  * **Form:** Multiple commercial sources
  * **Pathway:** NMN → NAD+ (one step closer than NR)
  * **Evidence:** Raises NAD+ in humans; David Sinclair's lab has extensively researched it
  * **Human RCT landscape (mixed):** Yoshino 2021 (250 mg/day, postmenopausal prediabetic women): ↑ muscle insulin sensitivity, no change in muscle NAD+ or body composition. Irie 2020 (300 mg, 60 d): safe, blood NAD+ NS. Yoshino 2024 / Wada 2024 (PMID [38135899](https://pubmed.ncbi.nlm.nih.gov/38135899/), older adults, sarcopenia parameters): 250 mg/day improved grip strength and gait speed trends, NAD+ rose. Uthever trial (300 mg, 60 d): blood NAD+ rose, 6-min walk improved. Multiple trials safe; functional outcomes inconsistent.
  * **Advantage:** More direct precursor; some evidence of superior bioavailability
  * **2026 PK disadvantage:** In the NAD-Brain head-to-head, NMN raised blood NAD+ ~69% vs NR's 161% at equivalent doses — if the goal is maximal NAD+ augmentation per gram, NR currently has the better human PK data



### Head-to-Head Precursor Comparison (Christen et al., 2025)

A 14-day three-arm human trial directly comparing NR, NMN, and nicotinamide (Nam) found NR and NMN both significantly raised blood NAD+ (via the Preiss-Handler pathway) while **Nam did not** at the tested doses — undercutting cheap nicotinamide as a substitute for NR/NMN.

### Direct Oral NAD+ Delivery — RENEWAL-NAD+ Trial (2026)

**Trial:** RENEWAL-NAD+ ([NCT07336836](https://clinicaltrials.gov/study/NCT07336836)), double-blind RCT, n=60 (primary analysis n=50), ages 45–75. **Intervention:** 5 days of oral **LathMized® NAD+ (LNAD+)** — a physicochemically modulated NAD+ formulation preserving native molecular structure but altering supramolecular organization to bypass the precursor bottleneck. **Key results:** \- **Intracellular NAD+ (whole blood):** +53% vs placebo at Day 6 (p=5.48×10⁻¹⁴; Hedges' g=3.66) \- **Plasma NAD+:** unchanged (p=0.60) — the body retains NAD+ inside cells, not in plasma \- **Catabolites surged:** MeNAM p=5.39×10⁻¹³; 2PY p=2.95×10⁻¹⁶ — confirming downstream flux engagement \- **Compartment signatures differ:** cirNAD tracked inflammatory/metabolic markers; icNAD tracked red-cell indices and NAM \- **Safety:** Excellent (1 mild nausea event, comparable to placebo)

**Why this matters:** First successful oral _NAD+_ delivery in humans — bypassing the precursor pathway entirely. The compartment finding (intracellular up, plasma flat) reconciles with the Trętowicz 2026 finding that whole-blood NAD+ doesn't decline with age: the relevant compartment is intracellular, and the LNAD+ trial shows it can be pharmacologically raised in older adults in just 5 days. Source: GeroScience 2026 (Springer DOI [10.1007/s11357-026-02399-1](https://doi.org/10.1007/s11357-026-02399-1)).

### Doses in studies

**Trial:** jRCTs031220373, double-blind RCT, n=62 healthy adults ≥65 years. **Intervention:** 1,250 mg/day NMN for 24 weeks (highest sustained NMN dose in any human RCT to date). **Primary endpoint (auditory function):** No significant effect. **Secondary endpoints:** No significant improvement in physical performance, audiometry, six-minute walk, or epigenetic age measures. **Key metabolic result:** Robust, sustained increases in blood NAD+ and related metabolites across the entire 24 weeks. **Safety:** Well tolerated at 1,250 mg/day; authors call for continued caution in future trials. **Bottom line:** Mirrors Yoshino 2021 — NMN reliably raises blood NAD+, but **functional/clinical benefit at this dose and duration remains undemonstrated**. The pharmacokinetic signal is real; the clinical translation is still missing. Source: _npj Aging_ 2026 (DOI [10.1038/s41514-026-00482-7](https://doi.org/10.1038/s41514-026-00482-7)).

### Compartment-Specific NAD+ Biology — 2026 Synthesis

The converging 2026 evidence (Trętowicz _Nature Metabolism_ 2026; LNAD+ GeroScience 2026; npj Aging 2026) converges on a refined model: \- **Whole-blood NAD+ is buffered** — it does not decline with age because red blood cells and other anuclear compartments maintain it across the lifespan. \- **Tissue-specific decline (muscle, brain, liver) is the real aging story** — driven by CD38, PARP, and reduced NMPT synthesis in nucleated cells. \- **Supplementation effects are compartment-specific** — LNAD+ raised intracellular but not plasma NAD+, suggesting intracellular stores are where the action is. \- **Functional translation lags PK** — even 1,250 mg/day NMN for 24 weeks reliably raises NAD+ without measurable functional gain in healthy older adults. \- **Disease-state testing is the next frontier** — the NAD-Brain trial showed NR raises brain NAD+ in Parkinson's patients; the field is shifting from healthy-aging endpoints to disease-specific ones.

### NAD+ IV Infusions

  * **Pros:** Directly raises blood NAD+; some report dramatic energy/mood effects
  * **Cons:** Expensive ($200-1000/session); short half-life; IV access required
  * **2026 review caveat:** A 2026 review of IV NAD+ administration concluded it is "less well characterized and lacks robust clinical validation" compared to oral precursors — most IV claims are clinic- or anecdote-driven rather than RCT-supported (PMID via Mol Biol Rep 53:1249).



## Sirtuins (SIRT1-7)

### Overview

  * NAD+-dependent deacylases that regulate metabolism, stress resistance, and aging
  * **They are the "sensor" that connects NAD+ levels to gene expression**

Sirtuin | Location | Key Functions | Activators  
---|---|---|---  
**SIRT1** | Nucleus, cytoplasm | Metabolism, inflammation, [autophagy](autophagy.html), DNA repair | Resveratrol, NAD+, fasting  
**SIRT2** | Cytoplasm | Cell cycle, myelination | NAD+  
**SIRT3** | Mitochondria | [Mitochondrial function](mitochondrial-health.html), antioxidant defense | Honokiol, NAD+  
**SIRT4** | Mitochondria | Insulin secretion, fatty acid oxidation | NAD+  
**SIRT5** | Mitochondria | Ammonia detox, metabolic regulation | NAD+  
**SIRT6** | Nucleus | DNA repair, telomere maintenance, glucose metabolism | NAD+, fisetin  
**SIRT7** | Nucleolus | rRNA transcription, stress response | NAD+  
  
### Sirtuin Activators

Compound | Target | Evidence  
---|---|---  
**Resveratrol** | SIRT1 | Moderate — bioavailability issues; ~20 clinical trials ongoing  
**Pterostilbene** | SIRT1 | Better bioavailability than resveratrol  
**Fisetin** | SIRT1, SIRT6 | Moderate — also a [senolytic](senolytics.html)  
**Honokiol** | SIRT3 | Emerging — mitochondrial sirtuin activator  
**SRT2104** (synthetic) | SIRT1 | Clinical development  
  
## The CD38 Problem

  * **CD38** is the primary NAD+-consuming enzyme that increases with age
  * Expressed on immune cells, especially senescent macrophages
  * **Senescent cells → SASP → more CD38 → less NAD+** — a vicious cycle
  * **Strategy:** Combine NAD+ precursors with [senolytics](senolytics.html) to reduce CD38-expressing cells
  * **CD38 inhibitors:** Apigenin, 78c (research compound)



## Practical NAD+ Optimization

### Uses

  1. **Combine with:** [Fasting](fasting-approaches.html) (sirtuins are most active during fasting)
  2. **Avoid:** Taking with high-dose niacin (competes for same pathway)



### Synergistic Approaches

  * [Exercise](exercise-science-and-longevity.html) ↑ NAMPT → more endogenous NAD+ synthesis
  * [Sauna](cold-and-heat-therapy.html) ↑ NAD+ through heat stress
  * [Senolytics](senolytics.html) ↓ CD38 → less NAD+ degradation
  * [Quality sleep](sleep-optimization.html) maintains circadian NAMPT expression



## NAD+ IV Therapy: Evidence and Pharmacokinetics

> **Core thesis:** NAD+ is a central redox cofactor and signaling substrate whose tissue pools decline with age, inflammation, metabolic dysfunction, and high NAD-consuming enzyme activity. IV NAD+ therapy is marketed as a rapid way to restore cellular energy, detoxification capacity, cognition, and addiction recovery. The mechanistic rationale is real; the direct human evidence for IV NAD+ clinical outcomes is still early, mostly uncontrolled, and weaker than evidence that oral NAD+ precursors such as NR and NMN reliably shift the NAD metabolome.

**Bottom line:** treat IV NAD+ as an experimental, high-cost pharmacologic intervention, not a proven longevity therapy. It may be useful when a supervised clinic wants acute, observable physiologic effects or when oral precursor response is poor, but it should be compared against cheaper and better-studied options: [Exercise Science and Longevity](exercise-science-and-longevity.html), circadian correction, [Mitochondrial Health](mitochondrial-health.html) protocols, niacin/NR/NMN, and reduction of inflammatory NAD drains.

* * *

### Evidence at a Glance

Claim | Evidence strength | Current interpretation  
---|---|---  
NAD+ biology matters for aging, DNA repair, sirtuins, PARPs, mitochondrial redox | High mechanistic | Foundational biochemistry; not controversial  
NAD pools can be raised in humans with NR/NMN/niacin-family compounds | Moderate | Multiple human trials show blood NAD-metabolome changes  
Oral NMN improves muscle insulin sensitivity in a defined subgroup | Moderate | Small but rigorous RCT in overweight/obese postmenopausal women with prediabetes  
NR improves cognition in MCI or neurodegenerative disease | Low-moderate | Raises NAD+; clinical outcomes inconsistent/early  
IV NAD+ produces superior intracellular NAD restoration vs oral precursors | Low | Assumed commercially; not yet demonstrated robustly  
IV NAD+ treats addiction withdrawal | Low | Long tradition and case reports; high-quality modern RCT evidence lacking  
IV NAD+ is safe long-term | Unknown | Short-term tolerability data exist; long-term repeated high-dose data are absent  
  
The most useful skeptical framing comes from Radenkovic, Reason, and Verdin's PRISMA-style review of NAD therapeutics: NAD pharmacology is promising and appears relatively safe, but human trials are heterogeneous, many indications have only one small study, and direct comparisons against exercise/diet are still needed (PMID: [32942582](https://pubmed.ncbi.nlm.nih.gov/32942582/)).

* * *

### Redox Currency

NAD exists mostly as a redox pair:

  * **NAD+** — oxidized electron acceptor
  * **NADH** — reduced electron donor



The NAD+/NADH ratio is a proxy for cellular redox state. A high-energy, insulin-sensitive cell can flexibly move electrons through glycolysis, the TCA cycle, beta-oxidation, and oxidative phosphorylation. A metabolically impaired cell may have altered NAD+/NADH balance, mitochondrial bottlenecks, excess ROS, and poor substrate switching.

### NAD-Consuming Enzymes

NAD+ is also consumed by signaling enzymes:

  * **Sirtuins** — deacetylases linked to mitochondrial biogenesis, circadian rhythm, DNA repair, and stress resistance. See [NAD+ and Sirtuin Activators](nad-and-sirtuin-activators.html).
  * **PARPs** — DNA-damage sensors and repair enzymes. Chronic DNA damage can drain NAD+.
  * **CD38/CD157** — ectoenzymes that degrade NAD+ and rise with inflammatory/aging phenotypes.
  * **SARM1** — axonal degeneration mediator; relevant to neurodegeneration and injury.



This creates a first-principles model: NAD+ falls not merely because less is produced, but because aging tissues often have **higher demand** from inflammation, DNA damage, immune activation, circadian disruption, and mitochondrial inefficiency.

### NAD Salvage Pathway

The dominant pathway in many tissues is salvage from nicotinamide:

  1. **Nicotinamide (NAM)**
  2. **NAMPT** converts NAM → NMN
  3. **NMNAT** converts NMN → NAD+



NR enters via conversion to NMN; NMN enters near the end of the pathway. Niacin enters through the Preiss–Handler pathway. Tryptophan can synthesize NAD de novo through the kynurenine pathway, but this route is metabolically costly and inflammation-sensitive.

**Clinical implication:** giving NAD+ directly may not bypass all bottlenecks. Extracellular NAD+ can be rapidly degraded into NAM, NMN, NR, ADPR, and methylated metabolites. The therapeutic question is whether IV NAD+ produces a superior intracellular NAD signal compared with precursors — not whether NAD+ itself is important.

* * *

### The Commercial Claim

IV clinics often claim that direct NAD+ infusion bypasses digestion and produces near-100% bioavailability. This is only partly meaningful. The compound enters blood, but the relevant target is **intracellular NAD pools in specific tissues** , especially brain, skeletal muscle, liver, immune cells, and pancreatic beta cells.

### What Pilot Pharmacokinetic Work Suggests

Small human infusion studies suggest infused NAD+ is rapidly metabolized. Plasma NAD+ may not simply rise in proportion to the dose; downstream metabolites such as nicotinamide, methyl-nicotinamide, ADPR, and urinary NAD-related products increase. This supports the idea that IV NAD+ acts partly as a high-dose substrate pulse into extracellular degradation and salvage pathways rather than as intact NAD+ directly entering cells.

A 2026 Frontiers in Aging retrospective pilot study compared commercial IV NAD+ vs IV NR in 14 real-world clients. It found:

  * IV NR was better tolerated than IV NAD+.
  * NAD+ IV produced moderate-to-severe GI symptoms, increased heart rate, chest pressure, throat/chest symptoms, and longer infusion times.
  * NR IV produced mostly mild tingling/cramping and shorter infusion times.
  * No short-term signal in ALT, AST, hsCRP, BUN/creatinine, TSH, or blood pressure.
  * The study had major limitations: retrospective design, n=14, no placebo arm, commercial clinic setting, and authors employed by the clinic/provider ecosystem.



**Interpretation:** IV NAD+ clearly has physiologic effects during infusion. It is not yet proven that those effects translate into better mitochondrial, cognitive, addiction, or longevity outcomes than oral precursor therapy.

* * *

### 1\. Addiction and Withdrawal Support

This is the oldest use case in integrative practice. Protocols descend from mid-20th-century observations and modern commercial detox clinics.

Application | Typical clinic claim | Evidence status  
---|---|---  
Alcohol withdrawal/craving | Reduced withdrawal symptoms and relapse drive | Case reports, clinic series, weak controlled evidence  
Opioid withdrawal | Reduced autonomic symptoms and post-acute withdrawal | Mostly anecdotal/observational  
Stimulant recovery | Dopamine and mitochondrial support | Mechanistic speculation + anecdotes  
Benzodiazepine taper support | Nervous-system stabilization | Anecdotal; caution required  
  
Mechanistic plausibility includes mitochondrial support, redox correction, neurotransmitter synthesis support, and reduction of oxidative stress. But addiction outcomes are multifactorial: trauma, environment, sleep, nutrition, social structure, psychiatric comorbidity, and pharmacologic stabilization usually dominate.

**Practical conclusion:** IV NAD+ may be considered an adjunct in supervised addiction medicine, not a standalone detox cure. It should not replace evidence-based alcohol/benzodiazepine withdrawal management where seizures, delirium tremens, or autonomic instability are risks.

### 2\. Metabolic Health and Insulin Sensitivity

The strongest human signal for an NAD precursor is not IV NAD+ but oral NMN. Yoshino et al. performed a 10-week randomized, double-blind, placebo-controlled trial of **250 mg/day NMN** in overweight/obese postmenopausal women with prediabetes. NMN increased skeletal muscle insulin signaling and insulin-stimulated glucose disposal measured by clamp methods (PMID: [33888596](https://pubmed.ncbi.nlm.nih.gov/33888596/)).

This is a useful anchor because it measured a hard metabolic physiology endpoint, not only subjective energy. However:

  * n was small: 25 completers.
  * Population was narrow: postmenopausal women with prediabetes and overweight/obesity.
  * It does not prove benefit in men, lean people, athletes, or healthy longevity users.
  * It does not prove IV NAD+ is superior to oral NMN.



### 3\. Neurodegeneration, MCI, and Brain NAD+

NR trials show that blood NAD+ can rise in older adults and some neurologic cohorts. A randomized placebo-controlled NR trial in older adults with mild cognitive impairment reported increased blood NAD+ but no clear cognition change over the short trial window (PMID: [37994989](https://pubmed.ncbi.nlm.nih.gov/37994989/)).

A skeptical first-principles view: raising blood NAD is necessary but not sufficient. Brain outcomes depend on transport, cell-type-specific metabolism, neuroinflammation, sleep, vascular perfusion, glymphatic clearance, glucose/ketone metabolism, and amyloid/tau/alpha-synuclein context. See [Sleep Optimization](sleep-optimization.html), [Mitochondrial Health](mitochondrial-health.html), and [Metabolic Health and Insulin](metabolic-health-and-insulin.html).

### 4\. Chronic Fatigue, Lyme, and Post-Infectious Syndromes

IV NAD+ is often marketed for chronic fatigue, chronic Lyme, long-COVID-like syndromes, and post-infectious malaise. Plausibility comes from mitochondrial dysfunction, immune activation, oxidative stress, and autonomic imbalance.

Evidence remains mostly anecdotal. Patients may report dramatic acute energy changes, but without controlled designs it is difficult to separate NAD effects from hydration, magnesium, B vitamins, placebo/context effects, rest, improved sleep after treatment, or regression to the mean.

For biofilm/chronic infection contexts, avoid assuming fatigue is merely an NAD deficiency. Look for persistent immune triggers, sinus/gut biofilms, mycotoxin load, dysautonomia, iron dysregulation, sleep apnea, nutrient deficiencies, and endocrine issues. Related: [Biofilms and Chronic Infections](biofilms-and-chronic-infection-overview.html), [Lyme and Co-infections](lyme-and-co-infections.html), [Mitochondrial Health](mitochondrial-health.html).

### 5\. General Longevity and Performance

The direct longevity claim is the weakest. NAD+ biology sits upstream of many aging pathways, but there is no human evidence that intermittent IV NAD+ extends lifespan or meaningfully slows biological aging. Biomarker improvements are not the same as mortality or healthspan outcomes.

A rational longevity stack would place IV NAD+ behind:

  1. Sleep/circadian correction
  2. Resistance training + Zone 2
  3. Protein and micronutrient adequacy
  4. Metabolic health and visceral fat reduction
  5. Sauna/thermal hormesis if tolerated
  6. Oral NAD precursor or niacin-family experiment with labs
  7. IV NAD+ only if there is a clear hypothesis, objective tracking, and medical supervision



* * *

### Oral Precursors vs IV NAD+

Factor | Oral NR/NMN/niacin | IV NAD+  
---|---|---  
Evidence for raising NAD metabolome | Moderate | Low-moderate, small studies  
Evidence for clinical outcomes | Mixed, indication-specific | Mostly weak/observational  
Cost | Low to moderate | High  
Convenience | Daily at home | Clinic infusion  
Adverse effects | GI, flushing for niacin, possible methylation load | Nausea, chest pressure, flushing, headache, vein irritation  
Dose flexibility | Easy | Requires practitioner/clinic  
Best use case | Long-term maintenance experiment | Acute supervised intervention / non-responder trial  
  
### NR Evidence Snapshot

Airhart et al. showed oral NR changed the blood NAD metabolome in healthy volunteers (PMID: [29211728](https://pubmed.ncbi.nlm.nih.gov/29211728/)). Later trials found NR generally tolerable at commonly studied doses, including higher-dose short-term safety work, but clinical effects vary by population and endpoint.

### NMN Evidence Snapshot

NMN has human data for safety and metabolic signaling, including the Yoshino prediabetes trial (PMID: [33888596](https://pubmed.ncbi.nlm.nih.gov/33888596/)). As with NR, the evidence supports **metabolome modulation** more strongly than broad anti-aging outcomes.

### Niacin / Nicotinic Acid

Niacin is cheap, old, and potent but produces flushing and has different pharmacology. It is under-discussed in longevity circles because it lacks the supplement-market glamour of NR/NMN. It should be evaluated separately, particularly for lipid effects, flushing tolerance, glucose effects, liver monitoring at high doses, and methylation dynamics.

* * *

### Before Starting

Domain | Possible labs / measures | Why it matters  
---|---|---  
CBC/CMP | CBC, AST/ALT, bilirubin, creatinine, BUN | Baseline safety  
Metabolic | fasting glucose, insulin, HbA1c, triglycerides, ApoB | Identify metabolic target  
Inflammation | hs-CRP, ESR, ferritin | NAD drain context  
Nutrients | B12, folate, homocysteine, magnesium RBC if available | Methylation and cofactor status  
Mitochondrial proxy | lactate, VO2max, exercise tolerance | Functional readout  
Sleep/recovery | HRV, sleep efficiency, resting HR | Autonomic response  
  
### After a Trial

Re-check objective endpoints at 4–8 weeks:

  * Symptoms: energy, sleep, cognitive clarity, cravings, exercise recovery
  * Wearables: HRV, resting HR, sleep architecture trends
  * Labs: HbA1c if metabolic target; liver/kidney markers if repeated IVs; homocysteine if high-dose precursors
  * Performance: Zone 2 power/pace at fixed HR; grip strength; reaction time; cognitive task consistency



**Avoid:** declaring success after one euphoric post-infusion day. Hydration, attention, expectation, and acute sympathetic shifts can all feel like a breakthrough.

* * *

### Uses

These are common real-world patterns, not evidence-established optimal dosing.

Goal | Notes  
---|---  
First exposure / tolerability test | Start here if sensitive, anxious, dysautonomic, or medication-heavy  
General wellness / energy | Track objective outcomes; avoid indefinite autopay protocols  
Addiction recovery adjunct | Only with medical withdrawal risk assessment  
Chronic fatigue / post-infectious | Stop if no measurable improvement  
High-dose commercial protocols | Experimental; higher side-effect burden; require supervision  
  
### Infusion Rate

Many adverse symptoms are rate-dependent. Slower is usually better tolerated.

Common symptoms during NAD+ infusion:

  * Nausea or abdominal tightness
  * Chest pressure or throat tightness
  * Warmth/flushing
  * Headache
  * Anxiety-like sympathetic activation
  * Muscle cramping
  * Metallic or unusual taste



**Rate response:** pause or slow the drip if symptoms appear. Severe chest pain, dyspnea, syncope, allergic symptoms, or abnormal vitals require medical evaluation, not “pushing through.”

### Cofactors Often Used

Cofactor | Rationale | Caution  
---|---|---  
Magnesium | ATP handling, cramping, autonomic stability | Monitor in kidney disease  
B-complex | Methylation and redox coenzymes | High B6 chronically can cause neuropathy  
Methylfolate/B12 | Supports methylation of NAM metabolites | Can be overstimulating in some  
Glutathione | Redox support | May cause sulfur sensitivity symptoms  
Vitamin C | Antioxidant, collagen, immune support | Oxalate/kidney stone considerations at high dose  
  
### Methylation Consideration

High NAD precursor use can increase nicotinamide turnover and methylated metabolites. In sensitive patients, monitor or consider:

  * Homocysteine
  * Folate/B12 status
  * Riboflavin/B2 status
  * Glycine intake
  * Choline/betaine intake



Do not assume methyl donors are universally beneficial. Some people become anxious, insomniac, or irritable when methylation support is pushed too hard.

### Contraindications and Cautions

  * Pregnancy or breastfeeding: insufficient evidence
  * Active cancer: theoretical concern because rapidly dividing cells use NAD metabolism; oncology supervision required
  * Severe kidney disease: altered clearance and electrolyte risk
  * Severe liver disease: metabolite handling concerns
  * Uncontrolled hypertension or unstable cardiovascular disease: infusion symptoms may mimic or worsen cardiopulmonary stress
  * Complex psychiatric instability: acute activation may worsen anxiety/insomnia
  * Active alcohol/benzodiazepine withdrawal: requires conventional medical withdrawal management



* * *

### When IV NAD+ Is More Defensible

  * Clear clinical hypothesis: withdrawal support, severe fatigue trial, poor oral response, supervised mitochondrial protocol
  * Objective baseline and follow-up measures
  * Practitioner can explain dose, infusion rate, cofactors, adverse event handling, sterile compounding source
  * Patient has already corrected obvious foundations: sleep, food quality, protein, magnesium, sunlight/circadian cues, training load
  * Limited trial window with stop criteria



### When IV NAD+ Is Probably Low-Value

  * “Longevity” marketing with no endpoints
  * Clinic sells expensive subscription packages before a response is known
  * No medical history review or medication interaction review
  * Patient expects IV NAD+ to compensate for sleep deprivation, alcohol, overtraining, or uncontrolled metabolic disease
  * No willingness to compare against cheaper oral NR/NMN/niacin experiments



### Stop Criteria

Stop or reassess if:

  * No measurable benefit after 3–6 sessions
  * Symptoms worsen, especially insomnia, anxiety, palpitations, chest pressure, or migraines
  * Liver/kidney markers worsen
  * The protocol becomes financially burdensome without clear outcomes
  * Benefits last only hours and do not compound into functional improvement



* * *

### Open Questions and Contradictions

  1. **Does intact NAD+ enter human cells meaningfully after IV infusion, or is the effect mostly through extracellular degradation into NAM/NR/NMN/ADPR?**
  2. **Is IV NR or IV NMN better tolerated and more biologically efficient than IV NAD+?** Early commercial data suggest IV NR may be better tolerated, but evidence is tiny and conflicted.
  3. **Which tissue matters?** Blood NAD may rise while brain, skeletal muscle, liver, and immune-cell responses diverge.
  4. **What is the optimal pulse schedule?** Continuous high NAD precursor exposure may not mimic hormetic biology.
  5. **Could chronic high-dose NAD repletion support cancer cell metabolism in some contexts?** This is biologically plausible but not clinically resolved.
  6. **How should NAD repletion interact with[Metformin and Rapamycin](metformin-and-rapamycin.html), fasting, sauna, exercise, and mitochondrial stressors?** Timing may matter.
  7. **Are benefits strongest in deficient/dysregulated states?** Likely yes. Healthy optimizers may show weaker clinical returns.



* * *

### Notes

  * [ ] Add a dedicated comparison note for niacin vs NR vs NMN vs NADH vs IV NAD+.
  * [ ] Track emerging IV NAD+/IV NR trials separately from oral precursor trials.
  * [ ] Look for patents and older addiction-medicine records behind the Hitt/Braverman NAD detox lineage.
  * [ ] Investigate whether CD38 inhibition plus precursor therapy has better mechanistic leverage than high-dose IV NAD+ alone.
  * [ ] Add adverse-event reports if pharmacovigilance signals appear.



## NAD+ Precursor Market in Crisis — Nature Metabolism Evidence Correction

### Overview

A May 2026 _Nature Metabolism_ study (Trętowicz et al.) challenged the foundational claim that blood NAD+ levels universally decline with age — the premise underlying the entire NAD+ precursor supplement market (NMN, NR, nicotinamide). This directly threatens brands including Bryan Johnson's Blueprint, Tru Niagen, Elysium Basis, Thorne, and Novos. Two additional 2026 studies (Berven et al. and Christen et al.) further refined the evidence base, clarifying which precursors work, how, and in which compartments.

### Trętowicz et al. — Whole-Blood NAD+ Stability (Primary Source)

  * **Citation:** Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. _Nature Metabolism_ (2026). DOI: [10.1038/s42255-026-01537-5](https://doi.org/10.1038/s42255-026-01537-5). PMID: [42135539](https://pubmed.ncbi.nlm.nih.gov/42135539/). Epub 2026 May 14.
  * **Design:** Seven independent human cohorts (n > 300 total, ages 18–87). Validated mass-spectrometry assay. Multiple lifestyle interventions tested (exercise, protein supplementation).
  * **Core Finding:** Whole-blood NAD+ levels remain remarkably stable across age and lifestyle interventions. NR supplementation increased levels 4–6 fold in responders, confirming precursors _do_ raise blood NAD+ — but the "universal age decline" narrative is unsupported for whole blood.
  * **Confounders Identified:** Freeze-thaw cycles and assay methodology (enzymatic vs. mass-spec) contributed to variability in prior studies claiming age-related decline.
  * **Critical Nuance:** This study measured **whole blood** only. It does not address tissue-level NAD+ (muscle, liver, brain), where animal models show clear age-related depletion. Blood and tissue NAD+ are distinct compartments.



### Berven et al. — NAD-Brain Pharmacokinetic Study (NR vs NMN Head-to-Head)

  * **Citation:** Berven H, Svensen M, Eikeland H, et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. _iScience._ 2026;29(3):114764. PMID: [41858901](https://pubmed.ncbi.nlm.nih.gov/41858901/).
  * **Design:** Phase I crossover trial, 1,200 mg/day NR or NMN in healthy adults and Parkinson's disease patients. Blood NAD+ measured by LC-MS; brain NAD+ measured by ³¹P-MRS (phosphorus magnetic resonance spectroscopy).
  * **Key Findings:**
  * **Blood:** NR raised blood NAD+ ~2.3× more than NMN at equivalent gram doses (161% vs. 69% increase). Difference persisted after correcting for molecular weight.
  * **Brain:** Four weeks of sustained NR supplementation raised brain NAD+ levels in healthy participants — one of the first human demonstrations of cerebral NAD+ augmentation from oral precursors. In Parkinson's patients, brain NAD+ trended upward but did not reach significance.
  * **Pharmacokinetics:** Blood NAD+ plateaued after ~2 weeks; brain NAD+ increases became detectable only after ~4 weeks, indicating delayed tissue equilibration.
  * **Implication:** NR may be pharmacokinetically superior to NMN for both blood and brain NAD+ augmentation. Tissue-level effects lag blood-level changes by weeks.



### Christen et al. — Booster Comparison & Microbiome (Nestlé Health Science)

  * **Citation:** Christen S, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. _Nature Metabolism_ 2025;8:62–73. DOI: [10.1038/s42255-025-01421-8](https://doi.org/10.1038/s42255-025-01421-8).
  * **Design:** RCT, 67 healthy adults, 14-day supplementation: NR (1 g/day, n=17), NMN (1 g/day, n=15), nicotinamide/Nam (0.5 g/day, n=17), or placebo (n=18).
  * **Key Findings:**
  * NR and NMN **both** significantly raised baseline whole-blood NAD+ over 14 days; Nam did not (only acute transient effect).
  * NR and NMN are **not directly absorbed** systemically. Instead, gut microbiota convert them to **nicotinic acid (NA)** , which enters the Preiss-Handler pathway — a "microbiome-mediated" mechanism.
  * NR and NMN also modulated gut bacteria composition and increased short-chain fatty acid (SCFA) production.
  * No effect of sex or age on response.
  * **Implication:** NR and NMN are comparably effective at raising blood NAD+ when administered chronically (contrasting with Berven's single-dose pharmacokinetic advantage for NR). The gut microbiome is a critical intermediary.



### Blood vs Tissue NAD+ — The Central Distinction

Compartment | Age-related decline? | Response to precursors | Measurement method  
---|---|---|---  
**Whole blood** | ❌ Not supported (Trętowicz 2026) | ✅ Yes — 4–6× with NR | Mass spectrometry (validated)  
**Skeletal muscle** | ✅ Supported (animal + some human) | ✅ Yes — moderate | Muscle biopsy / phosphorus-MRS  
**Brain** | ✅ Supported (animal models) | ✅ Yes — delayed (Berven 2026) | ³¹P-MRS only  
**Liver** | ✅ Supported (animal) | ✅ Yes | Biopsy (research only)  
**Skin** | Limited data | Partial | Biopsy  
  
The preclinical benefits of NAD+ augmentation — sirtuin activation, improved mitochondrial function, enhanced DNA repair via PARP — occur at the **cellular/tissue level** , not in whole blood. The Trętowicz study does not invalidate the mechanistic rationale for supplementation; it invalidates the marketing claim that "blood NAD+ decline with age → supplementation corrects aging."

### Competitive Intelligence — Brand & Clinic Exposure Map

Brand | Product | Precursor | Exposure Level | Repositioning  
---|---|---|---|---  
**Blueprint (Bryan Johnson)** | "NMN" stack | NMN | **High** | Shift to tissue-specific framing  
**Tru Niagen (ChromaDex)** | Niagen | NR | **Moderate** | Berven data actually supports NR superiority  
**Elysium Health** | Basis (NR + pterostilbene) | NR | **Moderate** | Emphasize brain NAD+ data  
**Thorne** | ResveraCel | NR + resveratrol | **Moderate** | Position as cellular, not blood-level  
**Novos** | NOVOS Core | Multi-ingredient | **Moderate** | De-emphasize NAD+ mechanism  
**NADclinic / IV clinics** | IV NAD+ infusions | NAD+ direct | **Low** | IV bypasses gut; different PK profile  
  
  * **High Exposure:** Brands whose core marketing premise is "NAD+ declines with age → our product fixes it" using blood-level claims.
  * **Repositioning Options:** Focus on microbiome benefits (Christen), muscle/brain NAD+ augmentation (Berven), or "optimization" rather than correction of universal decline.
  * **Dr. Shalender Bhasin (NPR, May 2026):** Emphasized early-stage human evidence; no lifespan RCTs exist.



### Claims Audit Recommendations

  1. **Remove or caveat** "NAD+ declines with age → supplementation reverses aging" framing for blood-based claims.
  2. **Cite 2026 _Nature Metabolism_ and _iScience_ papers explicitly** — these are now the methodological benchmarks.
  3. **Separate tiers clearly:** \- ✅ **Supported:** Blood NAD+ rises with NR/NMN supplementation (multiple RCTs). \- ✅ **Supported:** Brain NAD+ rises with sustained NR supplementation (Berven 2026, n=small). \- ⚠️ **Speculative:** Muscle NAD+ rises with oral precursors (animal data strong, human indirect). \- ❌ **Unsupported:** Lifespan extension, telomere lengthening, or "anti-aging" in humans.
  4. **Disclose microbiome pathway:** NR/NMN work partly via gut conversion to NA (Christen 2026) — relevant for patients on antibiotics or with gut dysfunction.



### Wikilinks

  * [NAD+ Precursors and Telomere Biology - Evidence Audit](nad-and-sirtuin-activators.html)
  * [NAD+ and Sirtuin Activators](nad-and-sirtuin-activators.html)
  * 11 - Longevity and Anti-Aging/NAD+ IV Therapy
  * [Rapamycin mTOR Inhibition - PEARL Trial Evidence](rapamycin-mtor-inhibition-pearl-trial-evidence-and-clinical-translation.html)
  * [Epitalon](epitalon-aedg-tetrapeptide-telomerase-pineal-axis-and-geroprotective-evidence.html)



## NAD+ Precursors and Telomere Biology: Evidence Review

### Bottom-Line Verdict (Sept 2026)

Claim | Evidence Status (2026) | Source  
---|---|---  
Whole-blood NAD+ declines with age | **Disproved** (no slope 18-87y) | Trętowicz 2026 PMID [42135539](https://pubmed.ncbi.nlm.nih.gov/42135539/)  
Oral NMN/NR raise blood NAD+ | Confirmed (~2× at 14 days; partly via microbiome) | Christen 2026 PMID [41540253](https://pubmed.ncbi.nlm.nih.gov/41540253/)  
Oral NR raises brain NAD+ in humans | Confirmed after ~4 weeks (first human MRS evidence) | Berven 2026 PMID [41858901](https://pubmed.ncbi.nlm.nih.gov/41858901/)  
NMN/NR extend lifespan in healthy humans | No eligible RCT | Gallagher PRISMA PMID [41655607](https://pubmed.ncbi.nlm.nih.gov/41655607/)  
NMN improves endurance (domain-specific) | Confirmed, dose-dependent (medium/high dose) | Gao NMA PMID [42774067](https://pubmed.ncbi.nlm.nih.gov/42774067/)  
NADH improves cognitive fatigue | SMD 1.50 (sensitive to influential studies) | Gao NMA PMID [42774067](https://pubmed.ncbi.nlm.nih.gov/42774067/)  
NMN broadly improves metabolic markers in healthy adults | Largely null; minor diastolic BP & HOMA-IR signal | Yang MA PMID [42514320](https://pubmed.ncbi.nlm.nih.gov/42514320/)  
NMN improves albuminuria in diabetic kidney disease (DKD) | Phase 2a in progress (MIB-626, [NCT05759468](https://clinicaltrials.gov/study/NCT05759468)) | Chandra protocol PMID [42603990](https://pubmed.ncbi.nlm.nih.gov/42603990/)  
— | Confirmed; no AE/hepatic signal | Yang MA PMID [42514320](https://pubmed.ncbi.nlm.nih.gov/42514320/)  
Telomere lengthening in healthy humans | Not demonstrated; tissue biology only | Zhou review PMID [41714893](https://pubmed.ncbi.nlm.nih.gov/41714893/)  
  
### Practical Talking Points

  1. **"Will it raise my NAD+?"** — Yes (blood), via direct and microbiome-mediated pathways. Confirmed across multiple 2026 RCTs.
  2. **"Will it extend my life?"** — Not demonstrated. No eligible human trial.
  3. **"Will it make me feel better / perform better?"** — Domain-dependent: endurance yes (NMN dose-dependent); subjective fatigue no; strength no; cognitive fatigue maybe (NADH).
  4. **"IV NAD+?"** — No eligible clinical-outcomes trials for anti-aging/wellness. Largely practice-based.

## Sources

1. PubMed 42135539 (PubMed 42135539)
2. PubMed 29555780 (PubMed 29555780)
3. PubMed 41858901 (PubMed 41858901)
4. PubMed 38135899 (PubMed 38135899)
5. NCT07336836 (NCT07336836)
6. DOI 10.1007/s11357-026-02399-1 (DOI 10.1007/s11357-026-02399-1)
7. DOI 10.1038/s41514-026-00482-7 (DOI 10.1038/s41514-026-00482-7)
8. PMC5107309 (PMC5107309)
9. PubMed 32942582 (PubMed 32942582)
10. PubMed 33888596 (PubMed 33888596)
11. PubMed 37994989 (PubMed 37994989)
12. PubMed 29211728 (PubMed 29211728)
13. DOI 10.1038/s42255-026-01537-5 (DOI 10.1038/s42255-026-01537-5)
14. DOI 10.1038/s42255-025-01421-8 (DOI 10.1038/s42255-025-01421-8)
15. PubMed 41540253 (PubMed 41540253)
16. PubMed 41655607 (PubMed 41655607)
17. PubMed 42774067 (PubMed 42774067)
18. PubMed 42514320 (PubMed 42514320)
19. NCT05759468 (NCT05759468)
20. PubMed 42603990 (PubMed 42603990)
21. PubMed 41714893 (PubMed 41714893)